Cerebellar Mutism Syndrome Study
Launched by RIGSHOSPITALET, DENMARK · Nov 24, 2014
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The Cerebellar Mutism Syndrome Study is looking into why some children develop a condition called Cerebellar Mutism Syndrome (CMS) after having surgery for brain tumors in the back part of the brain, known as the posterior fossa. This condition can affect their ability to speak and communicate. The study aims to understand how often this happens, what the typical recovery looks like, and the best ways to treat it.
To participate in the study, children must be under 18 years old and have a tumor located in the cerebellum, the fourth ventricle, or the brainstem. The study is open to all genders, and parents or guardians will need to give their consent for their child to join. If eligible, participants can expect to be part of a research team that will closely monitor their condition and treatment progress. The study is currently recruiting participants, and there are no specific exclusion criteria, making it accessible for many families dealing with this challenging situation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \< 18 years at the date of first imaging showing this tumour
- • Tumour in the cerebellum/4th ventricle/brainstem with intention to treat with surgical resection or open biopsy. Second and further surgeries are also included.
- • Informed consent from custodial parent(s)
- Exclusion Criteria:
- • None
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Copenhagen, , Denmark
Uppsala, , Sweden
Aarhus, , Denmark
Odense, , Denmark
Vienna, , Austria
Gothenburg, , Sweden
Utrecht, , Netherlands
Oulu, , Finland
Kuopio, , Finland
Tampere, , Finland
Stockholm, , Sweden
Bergen, , Norway
Aalborg, , Denmark
Linköping, , Sweden
Leuven, , Belgium
Oslo, , Norway
Turku, , Finland
Trondheim, , Norway
Groningen, , Netherlands
Tromsø, , Norway
Rome, , Italy
Kaunas, , Lithuania
Umeå, , Sweden
Budapest, , Hungary
Nijmegen, Gelderland, Netherlands
Skåne, , Sweden
Liverpool, , United Kingdom
Praha, , Czechia
Leipzig, , Germany
Patients applied
Trial Officials
Kjeld Schmiegelow, MD, Dr. med
Study Chair
Rigshospitalet, Denmark
Marianne Juhler, MD, Dr. med
Principal Investigator
Rigshospitalet, Denmark
Karsten Nysom, MD
Study Chair
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials